Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 12/20 | 0.50 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4299527 | 1.00 | KCNH2 (0.50) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL4294833 | 0.94 | KCNH2 (0.55) | KCNH2KCNQ1CACNA1C | |
| Fumaric Acid SCHEMBL4298786 | 0.90 | KCNH2 (0.45) | KCNH2KCNQ1CACNA1C | |
| Fumaric Acid SCHEMBL4298791 | 0.90 | KCNH2 (0.45) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL10285297 | 0.84 | KCNH2 (0.59) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL4309139 | 0.84 | KCNH2 (0.49) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL20679437 | 0.82 | KCNH2 (0.56) | KCNH2KCNQ1CACNA1C | |
| Fumaric Acid SCHEMBL4304312 | 0.81 | KCNH2 (0.54) | KCNH2KCNQ1CACNA1C | |
| Fumaric Acid SCHEMBL4304307 | 0.81 | KCNH2 (0.54) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL13264364 | 0.78 | KCNH2 (0.61) | KCNH2KCNQ1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | KCNH2 2142/4885KCNQ1 297/4885CACNA1C 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.